Takeda Pharmaceutical Company Limited (TKDA) — Cash Flow Quality Index
Takeda Pharmaceutical Company Limited (TKDA) has a Cash Flow Quality Index of 3.60x as of December 2025. Operating cash flow of €373.25 Billion exceeds net income of €103.64 Billion, indicating high earnings quality where cash backs reported profits. Explore Takeda Pharmaceutical Company Limited (TKDA) cash conversion ratio to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Takeda Pharmaceutical Company Limited Cash Flow Quality Index (2017–2025)
Historical Cash Flow Quality Index for Takeda Pharmaceutical Company Limited across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check TKDA capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Takeda Pharmaceutical Company Limited (2017–2025)
Year-by-year earnings quality comparison for Takeda Pharmaceutical Company Limited. For live market cap and the full company financial profile, see TKDA stock market capitalisation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 9.80x | €1.06 Trillion | €107.93 Billion | ▲ +363.4% |
| 2024 | 2.11x | €716.34 Billion | €338.87 Billion | ▼ -28.5% |
| 2023 | 2.96x | €977.16 Billion | €330.65 Billion | ▼ -39.5% |
| 2022 | 4.88x | €1.12 Trillion | €230.06 Billion | ▲ +19.5% |
| 2021 | 4.08x | €1.01 Trillion | €247.51 Billion | ▼ -73.0% |
| 2020 | 15.14x | €669.75 Billion | €44.24 Billion | ▲ +523.1% |
| 2019 | 2.43x | €328.48 Billion | €135.19 Billion | ▲ +20.2% |
| 2018 | 2.02x | €377.85 Billion | €186.89 Billion | ▼ -11.1% |
| 2017 | 2.27x | €261.36 Billion | €114.94 Billion | — |